CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Summary

The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be considered. Medulloblastoma outcomes have improved with contemporary therapies including modern neurosurgical techniques and risk-adapted radiotherapy and chemotherapy regimens. However, survivors remain at risk for long-term health problems such as neurocognitive deficits, hearing loss, impaired cardiorespiratory fitness and physical performance, cardiac and neuroendocrine dysfunction, musculoskeletal conditions, and infertility.

Eligibility

Inclusion Criteria:

* Diagnosis of any subtype of medulloblastoma between the ages of 3 to 22 years or between the ages of 22 to 44 years with the sonic hedgehog (SHH) subtype of medulloblastoma
* Radiotherapy on or according to the SJMB12 protocol
* 5 or more years since the initiation of radiation therapy and who did not have evidence of disease progression
* Provision of informed consent by participant/guardian or legal representative; Assent by minor participant
* Participants may choose to complete all or a subset of the proposed assessments; refusal to participate in some aspects of the study will not preclude participant inclusion
* Participants must also complete enrollment on SJLIFE

Exclusion Criteria:

* Participants or their legal guardian/representative are unwilling or unable to provide written informed consent.
* Participants who had relapsed or refractory disease during or following completion of treatment for medulloblastoma

Conditions2

Locations1 site

Browse More Trials